AUTHORS
Reid W Merryman, MD, Danielle Wallace, MD2, Robert Redd, MS3, Heather A. Walker, BS, MPH4, William Glenn Olson5, Vanessa Kats, RN6, Siri Sagedahl, BA7, Ioulia Vogiatzi, PhD8, Emily Sumpena, BA9, Weihsin Chuan10, Mingzeng Zhang, MD, PhD11, Inhye E Ahn, MD12, Amy Bessnow, MD, MPH13, Jennifer R. Brown, MD, PhD14, Jennifer L. Crombie, MD15, Matthew S Davids, MD, MMSc16, David C Fisher, MD17, Cynthia K. Hahn, MD, PhD18, Eric Jacobsen, MD19, Caron Jacobson, MD, MMSc20, Austin I Kim, MD21, Ann LaCasce, MD, MMSc22, Oreofe Odejide, MD, MPH23, Erin Parry, MD, PhD24, David Qualls, MD25, Christine Ryan, MD26, Aswin Sekar, MD, PhD27, Carla Casulo, MD28, David Bond, MD, BS29, Timothy J Voorhees, MD,MSc30, Daniel Clancy Trotier, MD31, Sumana Devata, MD32, Joshua D. Brody, MD33, Gottfried von Keudell, MD34, Philippe Armand, MD35, Mark Murakami, MD36, Yazeed Sawalha, MD37
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, United States
2 University of Rochester Medical Center, Rochester, United States
3 Dana-Farber Cancer Institute, Boston, United States
4 Dana-Farber Cancer Institute, Boston, United States
5 Dana-Farber Cancer Institute, Boston, United States
6 Dana-Farber Cancer Institute, Boston, United States
7 Dana-Farber Cancer Institute, Boston, United States
8 Dana-Farber Cancer Institute, Boston, United States
9 Dana-Farber Cancer Institute, Boston, United States
10 Dana-Farber Cancer Institute, Boston, United States
11 Dana-Farber Cancer Institute, Boston, United States
12 Dana-Farber Cancer Institute, Boston, United States
13 Dana-Farber Cancer Institute, Boston, United States
14 Dana-Farber Cancer Institute, Boston, United States
15 Dana-Farber Cancer Institute, Boston, United States
16 Dana-Farber Cancer Institute, Boston, United States
17 Dana-Farber Cancer Institute, Boston, United States
18 Dana-Farber Cancer Institute, Boston, United States
19 Dana-Farber Cancer Institute, Boston, United States
20 Dana-Farber Cancer Institute, Boston, United States
21 Dana-Farber Cancer Institute, Boston, United States
22 Dana-Farber Cancer Institute, Boston, United States
23 Dana-Farber Cancer Institute, Boston, United States
24 Dana-Farber Cancer Institute, Boston, United States
25 Dana-Farber Cancer Institute, Boston, United States
26 Dana-Farber Cancer Institute, Boston, United States
27 Dana-Farber Cancer Institute, Boston, United States
28 University of Rochester Medical Center, Rochester, United States
29 The Ohio State University, Columbus, United States
30 The Ohio State University, Columbus, United States
31 The Ohio State University, Columbus, United States
32 Medical College of Wisconsin, Milwaukee, United States
33 Icahn School of Medicine at Mount Sinai, New York, United States
34 Beth Israel Deaconess Medical Center, Boston, United States
35 Dana-Farber Cancer Institute, Boston, United States
36 Dana-Farber Cancer Institute, Boston, United States
37 The Ohio State University, Columbus, United States
ABSTRACT
Background: Bispecific antibody (BsAb)-based regimens are challenging the role of chemoimmunotherapy (CIT) as initial treatment for patients (pts) with high-tumor burden (HTB) follicular lymphoma (FL). We previously reported favorable results, including a best complete metabolic response (CMR) rate of 94%, from a 35 pt cohort that received 4 weekly doses of rituximab (R) and 9 cycles (Cs) of the CD3xCD20 BsAb, epcoritamab (epcor). Based on these results, a 65 pt expansion cohort was opened, which included less frequent dosing of epcor in C4-C9 and reduced dexamethasone (dex) prophylaxis (ppx) during epcor step-up dosing (SUD). Here we report additional follow-up for the first cohort and initial results from the expansion cohort (NCT05783609).
Methods: Eligibility criteria include untreated grade 1-3A FL, age≥18, stage II-IV, requirement for therapy per modified GELF criteria, ECOG PS 0-2. In C1, pts received 4 weekly doses of R (D-14, -7, 1, 8) and epcor (D1, 8, 15, 22). 2 epcor SUDs (0.16mg D1, 0.8mg D8) were used for pts 1-26 in the initial cohort and all subsequent pts received 3 SUDs (3mg D15). Epcor 48 mg was dosed weekly in C2-3, then either biweekly (initial cohort) or every 4 weeks (expansion cohort) in C4-9. In the initial cohort, pts received dex ppx for 4 days following each of the first 4 epcor doses. In the expansion, pts received a protocol-defined reduced dex ppx regimen, representing a 50% reduction in dex exposure. Responses were evaluated using PET-CT based on Lugano 2014 criteria.
Results: As of June 3 2026, 93 pts were enrolled. Baseline characteristics were similar between cohorts. The median age was 60 (28-83). At study entry, 81 pts (87%) had stage III/IV, 26 (28%) bulky disease (≥7 cm), 16 (17%) grade 3A FL, and 54 (58%) a FLIPI score of 3-5.
Among 79 response evaluable pts (with 14 pts awaiting 1st response assessment), best overall and CMR rates were 96% (95CI 89-99%) and 94% (95CI 86-98%), respectively. Responses occurred rapidly with 76/79 pts responding after 2 cycles (66 CMRs, 10 partial responses). 4 pts have progressed, including all 3 nonresponders on the 1st response assessment, all with transformed disease (n=1 CD20+ diffuse large B-cell lymphoma, n=2 classic Hodgkin lymphoma). All 3 pts achieved a CMR to subsequent therapies. Clonality studies between FL and aggressive lymphomas are ongoing. In addition, 1 responder relapsed at a single site with CD20+ FL at the end of treatment. The median follow-up for the initial and expansion cohorts are 18.6 months (m) and 6.7m, respectively. 18m PFS for the initial cohort is 97% (95%CI 92-100). 6m PFS for the expansion cohort is 94% (95%CI 87-100). No pts have died.
Among 86 pts who have completed C1, cytokine release syndrome (CRS) occurred in 33 pts (38%; G1 35%, G2 3%) with similar rates in the expansion cohort (17/51, 33%, G1 31%, G2 2%), despite reduced dex. No neurotoxicity was observed. Infections (related or unrelated) have occurred in 37 pts (40%; max G1 8%, G2 26%, G3 6%, G4 1%) with upper respiratory infections (n=18), COVID (n=5), and lung infections (n=3) being most common. Rates of any grade (15% vs 5%, p<0.001) and grade 2+ (10% vs 3%, p<0.001) infections per cycle appeared lower in the expansion cohort, which used reduced dex. Other common treatment-related adverse events (trAEs) included injection site reaction (49%), fatigue (40%), headache (33%), and infusion reactions (28%). G3+ trAEs included neutropenia (21%) and increased AST (2%).
Preliminary correlative analyses (n=21 pts) suggest that increased proportions of circulating CD8+ effector memory (EM) T cells at early timepoints (C2D1, C3D1) are associated with more frequent G2+ infections (particularly when these cells co-express cytotoxicity [granzyme B] and exhaustion [PD-1] markers) (p<0.01), while more frequent naïve CD8+ T cells are linked with fewer G2+ infections (p<0.01). Reduced dex was associated with a more favorable distribution of CD8+ T cells, with increased naive (p=0.01) and reduced EM (p=0.02) subsets. Reduced dex also correlated with increased circulating NKT and activated NK cells.
Conclusion: Fixed duration R+epcor achieves very frequent CMRs in pts with untreated HTB FL, and the 18m PFS of 97% in the initial cohort compares favorably to historical benchmarks for CIT at this early timepoint. In this setting, reduced dex ppx appears to be associated with similar rates of CRS and may lower the risk of infections, possibly by preserving key immune subsets.
DISCLOSURES
Reid W Merryman, MD: Abbvie - Honoraria; Genmab - Honoraria; Genentech/Roche - Research Funding; Merck - Research Funding; Genmab - Research Funding; Bristol-Myers Squibb - Research Funding; KITE - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Ipsen - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Bristol-Myers Squibb - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)